Anti-TNF antibodies, compositions, methods and uses

Details Anti-TNF antibodies, compositions, methods and uses Anti-TNF antibodies, compositions, methods and uses

2007-07-31

2007-07-31

Saoud, Christine J. (Department: 1647)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C530S388230, C530S387300

Reexamination Certificate

active

09920137

ABSTRACT:
The present invention relates to at least one novel anti-TNF antibodies, including isolated nucleic acids that encode at least one anti-TNF antibody, TNF, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

REFERENCES:
patent: 4603106 (1986-07-01), Cerami et al.
patent: 4822776 (1989-04-01), Cerami et al.
patent: 5231024 (1993-07-01), Moeller et al.
patent: 5342613 (1994-08-01), Creaven et al.
patent: 5654407 (1997-08-01), Boyle et al.
patent: 5656272 (1997-08-01), Le et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5698195 (1997-12-01), Le et al.
patent: 5698419 (1997-12-01), Wolpe et al.
patent: 5750105 (1998-05-01), Newman et al.
patent: 5888511 (1999-03-01), Skurkovich et al.
patent: 5919452 (1999-07-01), Le et al.
patent: 5958413 (1999-09-01), Anagnostopulos et al.
patent: 5993833 (1999-11-01), DeLacharriere et al.
patent: 6190691 (2001-02-01), Mak
patent: 6277969 (2001-08-01), Le et al.
patent: 6284471 (2001-09-01), Le et al.
patent: B-17649/92 (1996-05-01), None
patent: 0212489 (1987-03-01), None
patent: 0218868 (1987-04-01), None
patent: 0260610 (1988-03-01), None
patent: 0288088 (1988-10-01), None
patent: 0308378 (1989-03-01), None
patent: 0350690 (1990-01-01), None
patent: 0351789 (1990-01-01), None
patent: 0380068 (1990-08-01), None
patent: 0393438 (1990-10-01), None
patent: 0398327 (1990-11-01), None
patent: 0412486 (1991-02-01), None
patent: 0486526 (1991-03-01), None
patent: 0433900 (1991-06-01), None
patent: 0 526 905 (1992-08-01), None
patent: 0525570 (1993-02-01), None
patent: 0526905 (1993-02-01), None
patent: 0 610 210 (2001-05-01), None
patent: WO90/00902 (1990-02-01), None
patent: WO91/02078 (1991-02-01), None
patent: WO91/09967 (1991-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO92/16553 (1992-03-01), None
patent: WO92/07076 (1992-04-01), None
patent: WO92/11383 (1992-07-01), None
patent: WO92/13095 (1992-08-01), None
patent: WO93/02108 (1993-02-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 97/29131 (1997-08-01), None
Beutler, B. et al., “Identity of tumour necrosis factor and the macrophage-secreted factor cachectin,”Nature, 316:552-554 (1985).
Beutler, B. et al., “Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin,”Science, 229:869-871 (1985).
Morrison, Sherie L., “Transfectomas Provide Novel Chimeric Antibodies,”Science, 229:1202-1207 (1985).
Aggarwal, Bharat B. et al., “Human Tumor Necrosis Factor Production, Purification and Characterization,”J. of Biol. Chem., 260(4):2345-2354 (1985).
Beutler, B. et al., “Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells,”J. Exp. Med., 161:984-995 (1985).
Paulus, H., APreparation and Biomedical Applications of Bispecific Antibodies@,Behring Inst. Mitt, No. 78:118-132 (1985).
Hayashi, H. et al., “An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody,”Recent Adv. Chemother, 820-821 (1985).
Liang, Chi-Ming et al., “Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin,”Biochem.&Biophy. Res. Comm., 137(2):847-854 (1986).
Hirai, Makoto et al., “Production and characterization of monoclonal antibodies to human tumor necrosis factor,”J. of Immun. Methods, 96:57-62 (1987).
Piguet, Pierre-Francois et al., “Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease,”J. Exp. Med., 166:1280-1289 (1987).
Meager, Anthony et al., “Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF),”Hybridoma, 6(3):305-311 (1987).
Fendly, Brian M. et al., “Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor,”Hybridoma, 6(4):359-370 (1987).
Bringman, Timothy S. and Aggarwal, Bharat B., “Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes,”Hybridoma, 6(5):489-507 (1987).
Tracey, Kevin J. et al., “Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia,”Nature, 330:662-664 (1987).
Nagai, M. et al., “Antibody to tumor necrosis factor (TNF) reduces endotoxin fever,”Experientia, 44:606-607 (1988).
Shimamoto, Yoshinori et al., “Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock,”Immunology Letters, 17:311-318 (1988).
Di Giovine, Francesco, S. et al., “Tumour necrosis factor in synovial exudates,”Annals of the Rheumatic Diseases, 47:768-772 (1988).
Sunahara, N. et al., “Simple enzyme immunoassay methods for recombinant human tumor necrosis factor . and its antibodies using a bacterial cell wall carrier,” J Immunol Methods, 109:203-214 (1988).
Exley, A.R. et al., “Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys,”Medical Research Society, Abstract 184, p. 50 (1989).
Cross, A.S. et al., “Pretreatment with Recombinant Murine Tumor Necrosis Factor α Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection,”J of Exp Med., 169:2021-2027 (1989).
Whittle, Nigel, et al., “Construction and Expression of a CDR-Grafted Anti-TNF Antibody,”J. Cell Biochem, Supl. 13A:96 (1989).
Duncombe, Andrew S. et al., “Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia,”J Immunol, 143:3828-3834 (1989).
Aderka, Dan et al., “IL-6 Inhibits Lipopolysaccharide-Induced tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice,”J Immunol, 143:3517-3523 (1989).
Eck, Michael J. and Sprang, Stephen R., “The Structure of Tumor Necrosis Factor-. at 2.6 □ Resolution,”J Biol Chem, 264:17595-17605 (1989).
Gillies, Stephen D. et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes,”J Immunol Methods, 125:191-202 (1989).
Engelmann, Hartmut et al., “A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity,”J. of Bio. Chem., 264(20):11974-11980 (1989).
Kawasaki, Hajime et al., “Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin),”Infection and Immunity, 57(10):3131-3135 (1989).
Fong, Yuman et al., “Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1β and Interleukin 6 Appearance During Lethal Bacteremia,”J. Exp. Med., 170:1627-1633 (1989).
Collins, M.S. et al., “Immunoprophylaxis of Polymicrobic Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen ofPseudomonas aeruginosa,” Abstract E-63,Abstracts of Annual Meeting 1989.
Kameyama, Koh-zoh, et al., “Convenient plasmid vectors for construction of chimeric mouse/human antibodies,”FEBS Lett, 244:301-306 (1989).
Genebank Accession, No. N90300 (Nov. 1, 1989).
Engelmann, Hartmut et al., “Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine,”J. of Bio. Chem., 265(3):1531-1536 (1990).
Tavernier, Jan et al., “Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis,”J. Mol. Biol., 211:493-501 (1990).
Lucas, R. et al., “Generation and characterization of a neutralizing rat anti-rm TNF-α monoclonal antibody,”Immunology, 71:218-223 (1990).
Hinshaw, L.B. et al., 

Affiliated with

Also associated with

Rating

Anti-TNF antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-TNF antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-TNF antibodies, compositions, methods and uses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3792825